Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

Harvoni and Sovaldi compete for sales in certain markets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

1Q Revenues: $7.8 billion (+3%)

1Q Earnings: $3.6 billion (-16%)

Comments: Antiviral product sales, which include HIV and liver disease areas, were $7.2 billion, up 3%. In the U.S., antiviral product sales were down 18% in the quarter to $4.0 billion, primarily due to a decline in sales of Harvoni, partially offset by increases in Sovaldi sales, Truvadaand Genvoya, which was launched in the U.S. in November 2015. In Europe, antiviral product sales were down 6% to $1.6 billion, primarily due to a decline in sales of Sovaldi. In Japan, antiviral product sales were $1.1 billion. Sovaldi and Harvoni were launched in Japan in May and September 2015, respectively. Other product sales, which include Letairis, Ranexa and AmBisome, were up 19% to $498 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters